CA2790433A1 - Anticorps anti-addl et leurs utilisations - Google Patents

Anticorps anti-addl et leurs utilisations Download PDF

Info

Publication number
CA2790433A1
CA2790433A1 CA2790433A CA2790433A CA2790433A1 CA 2790433 A1 CA2790433 A1 CA 2790433A1 CA 2790433 A CA2790433 A CA 2790433A CA 2790433 A CA2790433 A CA 2790433A CA 2790433 A1 CA2790433 A1 CA 2790433A1
Authority
CA
Canada
Prior art keywords
antibody
addls
antibodies
binding
addl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2790433A
Other languages
English (en)
Inventor
Paul Acton
Zhiqiang An
Andrew J. Bett
Robert Breese
Elizabeth Chen Dodson
Gene Kinney
William Klein
Mary P. Lambert
Xiaoping Liang
Paul Shughrue
William R. Strohl
Kirsten L. Viola
Lei Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Northwestern University
Original Assignee
Merck Sharp and Dohme LLC
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC, Northwestern University filed Critical Merck Sharp and Dohme LLC
Priority claimed from CA2584859A external-priority patent/CA2584859C/fr
Publication of CA2790433A1 publication Critical patent/CA2790433A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2790433A 2004-10-25 2005-10-21 Anticorps anti-addl et leurs utilisations Abandoned CA2790433A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62177604P 2004-10-25 2004-10-25
US60/621,776 2004-10-25
US65253805P 2005-02-14 2005-02-14
US60/652,538 2005-02-14
CA2584859A CA2584859C (fr) 2004-10-25 2005-10-21 Anticorps anti-addl et leurs utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2584859A Division CA2584859C (fr) 2004-10-25 2005-10-21 Anticorps anti-addl et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2790433A1 true CA2790433A1 (fr) 2006-05-26

Family

ID=39161043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790433A Abandoned CA2790433A1 (fr) 2004-10-25 2005-10-21 Anticorps anti-addl et leurs utilisations

Country Status (3)

Country Link
CN (1) CN101137394A (fr)
CA (1) CA2790433A1 (fr)
ZA (1) ZA200703406B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190003862A (ko) * 2006-07-14 2019-01-09 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
WO2009051220A1 (fr) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Anticorps capable de se lier spécifiquement à un oligomère aβ, et son utilisation
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
ES2641612T3 (es) * 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
HUE036392T2 (hu) * 2009-08-07 2018-07-30 Kyowa Hakko Kirin Co Ltd Humanizált anti-amiloid ß oligomer antitest
EP2463369A4 (fr) * 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Anticorps oligomère humanisé anti-substance b-amyloïde
ES2573135T3 (es) * 2010-07-14 2016-06-06 Merck Sharp & Dohme Corp. Anticuerpo monoclonal anti-ADDL y usos del mismo
CN102167746B (zh) * 2010-11-11 2013-09-18 姜东成 Spg-抗体多聚体及其制备方法和应用
CN113248612A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN113244386A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114953087A (zh) * 2022-04-22 2022-08-30 西双版纳雨林拾光科技有限公司 一种用于数码打印影像的实木切片及其生产工艺

Also Published As

Publication number Publication date
CN101137394A (zh) 2008-03-05
ZA200703406B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
CA2584859C (fr) Anticorps anti-addl et leurs utilisations
EP1940466B1 (fr) Anticorps monoclonaux anti-addl et leur utilisation
US8105593B2 (en) Anti-ADDL monoclonal antibody and use thereof
CA2790433A1 (fr) Anticorps anti-addl et leurs utilisations
CA2805414C (fr) Anticorps monoclonal anti-addl et ses utilisations
CA2891627C (fr) Procede de traitement d'une maladie associee a une espece oligomere soluble d'amyloide beta 1-42
US8420093B2 (en) Anti-ADDL monoclonal antibody and use thereof
AU2011204912B2 (en) Anti-ADDL antibodies and uses thereof
AU2012232964B2 (en) Anti-ADDL antibodies and uses thereof
MX2007004909A (en) Anti-addl antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130318

FZDE Dead

Effective date: 20151021